{
    "name": "idecabtagene vicleucel",
    "comment": "Rx",
    "other_names": [
        "Abecma"
    ],
    "classes": [
        "CAR-T Cell Therapies"
    ],
    "source": "https://reference.medscape.com/drug/abecma-idecabtagene-vicleucel-4000133",
    "pregnancy": {
        "common": [
            "Data are not available in pregnant women",
            "No animal reproductive and developmental toxicity studies have been conducted",
            "Unknown if idecabtagene vicleucel may potentially transfer to fetus; based on the mechanism of action, if transduced cells cross placenta, fetal toxicity, including B-cell lymphocytopenia, may occur; not recommended for females who are pregnant, and consult with treating physician on pregnancy after infusion ",
            "Treated patients may have hypogammaglobulinemia; assess immunoglobulin levels in newborns of treated mothers",
            "Verify pregnancy status of females with reproductive potential before initiating treatment",
            "There are no data on effects on fertility"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "See prescribing information for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy",
                    "Insufficient exposure data are available to provide recommendations on duration of contraception following treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence in human milk, effects on the breastfed infants, and effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cytokine release syndrome",
                    "description": [
                        "Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment",
                        "Do not administer to patients with active infection or inflammatory disorders",
                        "Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids"
                    ]
                },
                {
                    "type": "Neurological toxicities",
                    "description": [
                        "Neurologic toxicities, including severe or life-threatening reactions, reported; these may occur concurrently with CRS, after CRS resolution, or in absence of CRS; monitor and provide supportive care and/or corticosteroids as needed",
                        "Most common neurological toxicities were encephalopathy, headache, tremor, aphasia, and delirium",
                        "Monitor for neurological events for at least 7 days at the certified healthcare facility following infusion for signs and symptoms of neurologic toxicities"
                    ]
                },
                {
                    "type": "Hemophagocytic lymphohistiocytosis/macrophage activation syndrome",
                    "description": [
                        "Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment ",
                        "HLH/MAS can occur with CRS or neurologic toxicities"
                    ]
                },
                {
                    "type": "Prolonged cytopenia",
                    "description": [
                        "Prolonged cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment"
                    ]
                },
                {
                    "type": "Restricted access program",
                    "description": [
                        "Available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Abecma REMS program",
                        "Further information is available at ",
                        "www.AbecmaREMS.com",
                        " [insert link] or contact Bristol-Myers Squibb at 1-888-423-5436 ",
                        "REMS requirements",
                        "Healthcare facilities that dispense and administer idecabtagene vicleucel must be enrolled and comply with the REMS requirements",
                        "Certified healthcare facilities must have onsite immediate access to tocilizumab",
                        "Ensure that a minimum of 2 doses of tocilizumab are available for each patient for administration within 2 hr after idecabtagene vicleucel IV infusion, if needed for treatment of CRS",
                        "Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer idecabtagene vicleucel are trained about the management of CRS and neurological toxicities"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Neurological toxicities, which may be severe or life-threatening, can occur following treatment; monitor for signs and symptoms of neurologic toxicity at least daily for 7 days following after idecabtagene vicleucel infusion at REMS-certified healthcare facility; continue monitoring for at least 4 weeks further; rule out other causes of neurologic symptoms; treat promptly and manage with supportive care and/or corticosteroids as needed",
                "Hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) reported: it is a potentially life-threatening condition with a high mortality rate if left undetected and untreated; in clinical trials, the median onset was 7 days (range: 4-9 days) and occurred in the setting of ongoing or worsening CRS; manifestations of HLH/MAS include: hypotension, hypoxia, multiple organ dysfunction, renal dysfunction, and cytopenia; treat HLH/MAS per institutional standards",
                "Available only through a restricted access program owing to CRS and neurologic toxicities",
                "Allergic reactions may occur during infusion; serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide in the product",
                "Prolonged cytopenias may occur following lymphodepleting chemotherapy and idecabtagene vicleucel infusion; monitor blood cell counts before and after idecabtagene vicleucel infusion; manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines",
                "Hypogammaglobulinemia and plasma cell aplasia can occur; monitor immunoglobulin levels after treatment and administer IV immunoglobulin for IgG<400 mg/dL; manage per local institutional guidelines",
                "Secondary malignancies or recurrence of leukemia may occur; monitor life-long for secondary malignancies; if secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 ",
                "Owing to potential neurological events (eg, altered mental status, seizures), patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following treatment; advise patients to refrain from driving or engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period"
            ],
            "specific": [
                {
                    "type": "Cytokine release syndrome",
                    "description": [
                        "CRS, including fatal or life-threatening reactions, occurred following treatment ",
                        "Median time to CRS onset was 1 day (range: 1-23 days)",
                        "Most common manifestations of CRS included pyrexia, hypotension, tachycardia, chills, hypoxia, fatigue, and headache",
                        "Grade â‰¥3 events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, acute respiratory distress syndrome, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome, and HLH/MAS",
                        "Identify CRS based on clinical presentation; evaluate for and treat other causes of fever, hypoxia, and hypotension",
                        "CRS has been associated with findings of HLH/MAS, and physiology of syndromes may overlap",
                        "In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS",
                        "Treat severe or life-threatening CRS with tocilizumab",
                        "At first sign of CRS, institute treatment with supportive care, tocilizumab, and/or corticosteroids as indicated",
                        "Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time"
                    ]
                },
                {
                    "type": "Infections",
                    "description": [
                        "Serious infections, including life-threatening or fatal infections, reported",
                        "Do not administer to patients with active infections or inflammatory disorders",
                        "Monitor for signs and symptoms of infection before and after idecabtagene vicleucel infusion",
                        "Administer prophylactic, empiric, and/or therapeutic antimicrobials according to standard institutional guidelines",
                        "Febrile neutropenia observed after idecabtagene vicleucel infusion and may be concurrent with CRS; if febrile neutropenia occurs, manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated",
                        "Viral reactivation",
                        "Cytomegalovirus (CMV) infection resulting in pneumonia and death occurred; monitor and treat for CMV reactivation in accordance with clinical guidelines",
                        "Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells",
                        "Perform screening for CMV, HBV, hepatitis C virus, and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing",
                        "Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Immunization with live viral vaccines",
                        "Safety of immunization with live viral vaccines during or following treatment has not been studied",
                        "Vaccination with live-virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during idecabtagene vicleucel treatment, and until immune recovery afterwards",
                        "HIV nucleic acid tests",
                        "HIV and the lentivirus used to make idecabtagene vicleucel have limited, short spans of identical genetic material (RNA)",
                        "Therefore, some commercial HIV nucleic acid tests may yield false-positive results in patients receiving idecabtagene vicleucel"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abatacept",
            "description": {
                "common": "abatacept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "ado-trastuzumab emtansine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "alemtuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ansuvimab",
            "description": {
                "common": "ansuvimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apaziquone",
            "description": {
                "common": "apaziquone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atoltivimab/maftivimab/odesivimab",
            "description": {
                "common": "atoltivimab/maftivimab/odesivimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "balstilimab",
            "description": {
                "common": "balstilimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bendamustine",
            "description": {
                "common": "bendamustine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benralizumab",
            "description": {
                "common": "benralizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benznidazole",
            "description": {
                "common": "benznidazole, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betamethasone",
            "description": {
                "common": "betamethasone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bevacizumab",
            "description": {
                "common": "bevacizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bezlotoxumab",
            "description": {
                "common": "bezlotoxumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bimekizumab",
            "description": {
                "common": "bimekizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "botulism immune globulin iv",
            "description": {
                "common": "botulism immune globulin iv, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brodalumab",
            "description": {
                "common": "brodalumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "busulfan",
            "description": {
                "common": "busulfan, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "C1 esterase inhibitor recombinant",
            "description": {
                "common": "C1 esterase inhibitor recombinant, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "C1 inhibitor human",
            "description": {
                "common": "C1 inhibitor human, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capecitabine",
            "description": {
                "common": "capecitabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caplacizumab",
            "description": {
                "common": "caplacizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carmustine",
            "description": {
                "common": "carmustine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cetuximab",
            "description": {
                "common": "cetuximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "chlorambucil, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cladribine",
            "description": {
                "common": "cladribine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clofarabine",
            "description": {
                "common": "clofarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "corticotropin",
            "description": {
                "common": "corticotropin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytarabine",
            "description": {
                "common": "cytarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytomegalovirus immune globulin (CMV IG)",
            "description": {
                "common": "cytomegalovirus immune globulin (CMV IG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "dacarbazine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daclizumab",
            "description": {
                "common": "daclizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daratumumab",
            "description": {
                "common": "daratumumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "denosumab",
            "description": {
                "common": "denosumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dimethyl fumarate",
            "description": {
                "common": "dimethyl fumarate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dinutuximab",
            "description": {
                "common": "dinutuximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diroximel fumarate",
            "description": {
                "common": "diroximel fumarate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dupilumab",
            "description": {
                "common": "dupilumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Ebola Zaire vaccine",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ecallantide",
            "description": {
                "common": "ecallantide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eculizumab",
            "description": {
                "common": "eculizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elotuzumab",
            "description": {
                "common": "elotuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "emapalumab",
            "description": {
                "common": "emapalumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "emicizumab",
            "description": {
                "common": "emicizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "filgotinib",
            "description": {
                "common": "filgotinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "floxuridine",
            "description": {
                "common": "floxuridine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludarabine",
            "description": {
                "common": "fludarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "fluorouracil, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "gemcitabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "gemtuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guselkumab",
            "description": {
                "common": "guselkumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hepatitis B immune globulin (HBIG)",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibritumomab tiuxetan",
            "description": {
                "common": "ibritumomab tiuxetan, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "icatibant",
            "description": {
                "common": "icatibant, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin IM (IGIM)",
            "description": {
                "common": "immune globulin IM (IGIM), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin IV (IGIV)",
            "description": {
                "common": "immune globulin IV (IGIV), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin SC",
            "description": {
                "common": "immune globulin SC, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inebilizumab",
            "description": {
                "common": "inebilizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon alfa n3",
            "description": {
                "common": "interferon alfa n3, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon alfacon 1",
            "description": {
                "common": "interferon alfacon 1, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1a",
            "description": {
                "common": "interferon beta 1a, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1b",
            "description": {
                "common": "interferon beta 1b, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iodoquinol",
            "description": {
                "common": "iodoquinol, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ipilimumab",
            "description": {
                "common": "ipilimumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "isotretinoin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurbinectedin",
            "description": {
                "common": "lurbinectedin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mechlorethamine topical",
            "description": {
                "common": "mechlorethamine topical, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "melphalan flufenamide",
            "description": {
                "common": "melphalan flufenamide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mepolizumab",
            "description": {
                "common": "mepolizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mineral oil topical",
            "description": {
                "common": "mineral oil topical, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitoxantrone",
            "description": {
                "common": "mitoxantrone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mogamulizumab",
            "description": {
                "common": "mogamulizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mometasone sinus implant",
            "description": {
                "common": "mometasone sinus implant, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "monomethyl fumarate",
            "description": {
                "common": "monomethyl fumarate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moxetumomab pasudotox",
            "description": {
                "common": "moxetumomab pasudotox, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "narsoplimab",
            "description": {
                "common": "narsoplimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "natalizumab",
            "description": {
                "common": "natalizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelarabine",
            "description": {
                "common": "nelarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitazoxanide",
            "description": {
                "common": "nitazoxanide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nivolumab",
            "description": {
                "common": "nivolumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "obinutuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab",
            "description": {
                "common": "ofatumumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olaratumab",
            "description": {
                "common": "olaratumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omalizumab",
            "description": {
                "common": "omalizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oportuzumab monatox",
            "description": {
                "common": "oportuzumab monatox, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panitumumab",
            "description": {
                "common": "panitumumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "peginterferon beta-1a",
            "description": {
                "common": "peginterferon beta-1a, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pembrolizumab",
            "description": {
                "common": "pembrolizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "pemetrexed, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentostatin",
            "description": {
                "common": "pentostatin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimecrolimus",
            "description": {
                "common": "pimecrolimus, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "poliovirus vaccine live oral trivalent",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of poliovirus vaccine live oral trivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "pralatrexate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rabies immune globulin, human (RIG)",
            "description": {
                "common": "rabies immune globulin, human (RIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ravulizumab",
            "description": {
                "common": "ravulizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "raxibacumab",
            "description": {
                "common": "raxibacumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "reltecimod",
            "description": {
                "common": "reltecimod, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "remestemcel-L",
            "description": {
                "common": "remestemcel-L, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "reslizumab",
            "description": {
                "common": "reslizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Rho(D) immune globulin",
            "description": {
                "common": "Rho(D) immune globulin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risankizumab",
            "description": {
                "common": "risankizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "ruxolitinib topical, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sarilumab",
            "description": {
                "common": "sarilumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siltuximab",
            "description": {
                "common": "siltuximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sintilimab",
            "description": {
                "common": "sintilimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus intravitreal",
            "description": {
                "common": "sirolimus intravitreal, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirukumab",
            "description": {
                "common": "sirukumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) and monkeypox vaccine, live, nonreplicating",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, attenuated",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "spesolimab",
            "description": {
                "common": "spesolimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptozocin",
            "description": {
                "common": "streptozocin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "sulfasalazine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sutimlimab",
            "description": {
                "common": "sutimlimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus ointment",
            "description": {
                "common": "tacrolimus ointment, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temozolomide",
            "description": {
                "common": "temozolomide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetanus immune globulin (TIG)",
            "description": {
                "common": "tetanus immune globulin (TIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioguanine",
            "description": {
                "common": "thioguanine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiotepa",
            "description": {
                "common": "thiotepa, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tinidazole",
            "description": {
                "common": "tinidazole, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "tofacitinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tositumomab",
            "description": {
                "common": "tositumomab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trabectedin",
            "description": {
                "common": "trabectedin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "treosulfan",
            "description": {
                "common": "treosulfan, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide extended-release injectable suspension",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "upadacitinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vaccinia immune globulin intravenous",
            "description": {
                "common": "vaccinia immune globulin intravenous, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella zoster immune globulin, human",
            "description": {
                "common": "varicella zoster immune globulin, human, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cytokine release syndrome",
            "percent": "85"
        },
        {
            "name": "Infections",
            "percent": "51"
        },
        {
            "name": "unspecified pathogen",
            "percent": "45"
        },
        {
            "name": "Fatigue",
            "percent": "45"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "41"
        },
        {
            "name": "Hypogammaglobulinemia",
            "percent": "35"
        },
        {
            "name": "Diarrhea",
            "percent": "34"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "29"
        },
        {
            "name": "Nausea",
            "percent": "27"
        },
        {
            "name": "Viral infections",
            "percent": "26"
        },
        {
            "name": "Encephalopathy",
            "percent": "25"
        },
        {
            "name": "Pyrexia",
            "percent": "25"
        },
        {
            "name": "Edema",
            "percent": "23"
        },
        {
            "name": "Headache",
            "percent": "23"
        },
        {
            "name": "Cough",
            "percent": "22"
        },
        {
            "name": "Decreased appetite",
            "percent": "19"
        },
        {
            "name": "Tachycardia",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "17"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "17"
        },
        {
            "name": "Hypotension",
            "percent": "17"
        },
        {
            "name": "Pneumonia",
            "percent": "16"
        },
        {
            "name": "Constipation",
            "percent": "16"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "15"
        },
        {
            "name": "Bacterial infections",
            "percent": "15"
        },
        {
            "name": "Vomiting",
            "percent": "14"
        },
        {
            "name": "Rash",
            "percent": "13"
        },
        {
            "name": "Weight decreased",
            "percent": "13"
        },
        {
            "name": "Insomnia",
            "percent": "13"
        },
        {
            "name": "Dyspnea",
            "percent": "12"
        },
        {
            "name": "Anxiety",
            "percent": "12"
        },
        {
            "name": "Oral pain",
            "percent": "11"
        },
        {
            "name": "General physical health deterioration",
            "percent": "11"
        },
        {
            "name": "Chills",
            "percent": "11"
        },
        {
            "name": "Motor dysfunction",
            "percent": "11"
        },
        {
            "name": "Xerosis",
            "percent": "11"
        },
        {
            "name": "Hypertension",
            "percent": "96"
        },
        {
            "name": "Neutropenia",
            "percent": "96"
        },
        {
            "name": "Leukopenia",
            "percent": "92"
        },
        {
            "name": "Lymphopenia",
            "percent": "63"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "63"
        },
        {
            "name": "Anemia",
            "percent": "45"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "16"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "15"
        },
        {
            "name": "Infections",
            "percent": "10"
        },
        {
            "name": "unspecified pathogen",
            "percent": "10"
        },
        {
            "name": "Tremor",
            "percent": "9"
        },
        {
            "name": "Renal failure",
            "percent": "9"
        },
        {
            "name": "Coagulopathy",
            "percent": "8"
        },
        {
            "name": "Sepsis",
            "percent": "7"
        },
        {
            "name": "Fungal infections",
            "percent": "6"
        },
        {
            "name": "Aphasia",
            "percent": "4.7"
        },
        {
            "name": "Delirium",
            "percent": "3.1"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "3.1"
        },
        {
            "name": "Gastrointestinal hemorrhage",
            "percent": "3.1"
        },
        {
            "name": "Hemophagocytic lymphohistiocytosis",
            "percent": "3.1"
        },
        {
            "name": "Thrombosis",
            "percent": "2.4"
        },
        {
            "name": "Ataxia",
            "percent": "2.4"
        },
        {
            "name": "Paresis",
            "percent": "2.4"
        },
        {
            "name": "Hypoxia",
            "percent": "1.6"
        },
        {
            "name": "Pulmonary edema",
            "percent": "1.6"
        },
        {
            "name": "Cardiomyopathy",
            "percent": "10"
        },
        {
            "name": "Seizure",
            "percent": "10"
        },
        {
            "name": "General physical health deterioration",
            "percent": "10"
        },
        {
            "name": "Hyponatremia",
            "percent": "10"
        },
        {
            "name": "Activated partial thromboplastin time increased",
            "percent": "10"
        },
        {
            "name": "ALT increased",
            "percent": "10"
        },
        {
            "name": "AST increased",
            "percent": "10"
        },
        {
            "name": "Hypoalbuminemia",
            "percent": "10"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "10"
        },
        {
            "name": "Hyperglycemia",
            "percent": "10"
        },
        {
            "name": "Hypokalemia",
            "percent": "10"
        },
        {
            "name": "Bilirubin increased",
            "percent": "10"
        },
        {
            "name": "Hypofibrinogenemia",
            "percent": "9"
        },
        {
            "name": "Hypocalcemia",
            "percent": "9"
        },
        {
            "name": "Cytokines release syndrome",
            "percent": "9"
        },
        {
            "name": "Viral infections",
            "percent": "6"
        },
        {
            "name": "Pneumonia",
            "percent": "3.9"
        },
        {
            "name": "Encephalopathy",
            "percent": "3.1"
        },
        {
            "name": "Bacterial infections",
            "percent": "3.1"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3.1"
        },
        {
            "name": "Fatigue",
            "percent": "2.4"
        },
        {
            "name": "Hypertension",
            "percent": "2.4"
        },
        {
            "name": "Renal failure",
            "percent": "1.6"
        },
        {
            "name": "Dyspnea",
            "percent": "1.6"
        },
        {
            "name": "Pyrexia",
            "percent": "1.6"
        },
        {
            "name": "Diarrhea",
            "percent": "1.6"
        },
        {
            "name": "Weight decreased",
            "percent": "0.8"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "0.8"
        },
        {
            "name": "Hypogammaglobulinemia",
            "percent": "0.8"
        },
        {
            "name": "Decreased appetite",
            "percent": "0.8"
        },
        {
            "name": "Dizziness",
            "percent": "0.8"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "0.8"
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        }
    ]
}